BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol 2021;32:1474-83. [PMID: 33753537 DOI: 10.1681/ASN.2020111566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Mariani MV, Di Lullo L, Lavalle C. Direct oral anticoagulants and chronic kidney disease: it is time to be brave. J Nephrol 2021. [PMID: 34357570 DOI: 10.1007/s40620-021-01137-4] [Reference Citation Analysis]
2 Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, Guo Y, Sriratanasathavorn C, Oh S, Okumura K, Lip GYH. 2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation. J Arrhythm 2021;37:1389-426. [PMID: 34887945 DOI: 10.1002/joa3.12652] [Reference Citation Analysis]
3 Starr JA, Pinner NA, Mannis M, Stuart MK. A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease. Ann Pharmacother 2021;:10600280211040093. [PMID: 34459281 DOI: 10.1177/10600280211040093] [Reference Citation Analysis]
4 Bikdeli B, Zahedi Tajrishi F, Sadeghipour P, Talasaz AH, Fanikos J, Lippi G, Siegal DM, Eikelboom JW, Monreal M, Jimenez D, Connors JM, Ageno W, Barnes GD, Piazza G, Angiolillo DJ, Parikh SA, Kirtane AJ, Lopes RD, Bhatt DL, Weitz JI, Mehran R, Krumholz HM, Goldhaber SZ, Lip GYH. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiol 2022. [PMID: 35648414 DOI: 10.1001/jamacardio.2022.1292] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lionet A, Urena Torres PA. [Uremic calciphylaxis]. Nephrol Ther 2022;18:180-8. [PMID: 35514006 DOI: 10.1016/j.nephro.2021.12.005] [Reference Citation Analysis]
6 Heher E, Elias N. Addressing Transplant Candidacy When Evaluating Safety of Direct Oral Anticoagulant Agents in Patients on Hemodialysis. J Am Soc Nephrol 2021;32:2389-90. [PMID: 34410934 DOI: 10.1681/ASN.2021060814] [Reference Citation Analysis]
7 Ellenbogen MI, Ardeshirrouhanifard S, Segal JB, Streiff MB, Deitelzweig SB, Brotman DJ. Safety and effectiveness of apixaban versus warfarin for acute venous thromboembolism in patients with end-stage kidney disease: A national cohort study. J Hosp Med 2022. [PMID: 35929542 DOI: 10.1002/jhm.12926] [Reference Citation Analysis]
8 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
9 De Vriese AS. Authors' Reply. J Am Soc Nephrol 2021;32:2390-1. [PMID: 34410935 DOI: 10.1681/ASN.2021060866] [Reference Citation Analysis]
10 Liao J, Kuo L, Liu C, Chen S, Chao T. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with advanced chronic kidney and liver diseases. European Heart Journal Supplements 2022;24:A11-8. [DOI: 10.1093/eurheartj/suab154] [Reference Citation Analysis]
11 Chandrasegaram A, Peters CD. The use of non-vitamin K oral anticoagulants in dialysis patients-A systematic review. Semin Dial 2022. [PMID: 35623902 DOI: 10.1111/sdi.13098] [Reference Citation Analysis]
12 Hanigan S, Park JM. Evaluating pharmacokinetic drug-drug interactions of direct oral anticoagulants in patients with renal dysfunction. Expert Opin Drug Metab Toxicol 2022;18:189-202. [PMID: 35543017 DOI: 10.1080/17425255.2022.2074397] [Reference Citation Analysis]
13 Akhtar Z, Leung LW, Kontogiannis C, Chung I, Bin Waleed K, Gallagher MM. Arrhythmias in Chronic Kidney Disease. Eur Cardiol 2022;17:e05. [DOI: 10.15420/ecr.2021.52] [Reference Citation Analysis]